Pancreatic Endocrine Tumor - Pipeline Review, H1 2015

Publisher Name :
Date: 15-Apr-2015
No. of pages: 59
Inquire Before Buying

Global Markets Direct's, ‘Pancreatic Endocrine Tumor - Pipeline Review, H1 2015', provides an overview of the Pancreatic Endocrine Tumor's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Endocrine Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Endocrine Tumor and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • The report provides a snapshot of the global therapeutic landscape of Pancreatic Endocrine Tumor

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Pancreatic Endocrine Tumor and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Pancreatic Endocrine Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Pancreatic Endocrine Tumor pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products


Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Pancreatic Endocrine Tumor

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Pancreatic Endocrine Tumor pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Pancreatic Endocrine Tumor - Pipeline Review, H1 2015

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pancreatic Endocrine Tumor Overview 6
Therapeutics Development 7
Pipeline Products for Pancreatic Endocrine Tumor - Overview 7
Pipeline Products for Pancreatic Endocrine Tumor - Comparative Analysis 8
Pancreatic Endocrine Tumor - Therapeutics under Development by Companies 9
Pancreatic Endocrine Tumor - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Pancreatic Endocrine Tumor - Products under Development by Companies 13
Pancreatic Endocrine Tumor - Companies Involved in Therapeutics Development 14
Biogenomics Limited 14
Ipsen S.A. 15
Jiangsu Hengrui Medicine Co., Ltd. 16
MediaPharma s.r.l. 17
Novartis AG 18
OXiGENE, Inc. 19
Pancreatic Endocrine Tumor - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
buparlisib hydrochloride - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
fosbretabulin tromethamine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
interferon alfa-2b (recombinant) - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
lanreotide acetate - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
MPHE-001B - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SHR-1020 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
X-82 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Pancreatic Endocrine Tumor - Recent Pipeline Updates 45
Pancreatic Endocrine Tumor - Discontinued Products 54
Pancreatic Endocrine Tumor - Product Development Milestones 55
Featured News & Press Releases 55
Jan 13, 2015: Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline Depot (lanreotide), at Gastrointestinal Cancers Symposium 55
Dec 16, 2014: Ipsen's Somatuline Depot is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for Pancreatic Endocrine Tumor, H1 2015 7
Number of Products under Development for Pancreatic Endocrine Tumor - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Pancreatic Endocrine Tumor - Pipeline by Biogenomics Limited, H1 2015 14
Pancreatic Endocrine Tumor - Pipeline by Ipsen S.A., H1 2015 15
Pancreatic Endocrine Tumor - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 16
Pancreatic Endocrine Tumor - Pipeline by MediaPharma s.r.l., H1 2015 17
Pancreatic Endocrine Tumor - Pipeline by Novartis AG, H1 2015 18
Pancreatic Endocrine Tumor - Pipeline by OXiGENE, Inc., H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Pancreatic Endocrine Tumor Therapeutics - Recent Pipeline Updates, H1 2015 45
Pancreatic Endocrine Tumor - Discontinued Products, H1 2015 54

List of Figures

Number of Products under Development for Pancreatic Endocrine Tumor, H1 2015 7
Number of Products under Development for Pancreatic Endocrine Tumor - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Top 10 Targets, H1 2015 21
Number of Products by Stage and Top 10 Targets, H1 2015 21
Number of Products by Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Top 10 Routes of Administration, H1 2015 25
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 26
Number of Products by Top 10 Molecule Types, H1 2015 27
Number of Products by Stage and Top 10 Molecule Types, H1 2015 28

  • Global Small Cell Lung Cancer Therapeutics Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2024
    Published: 16-Jan-2019        Price: US 3480 Onwards        Pages: 137
    Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell carcinoma. It can be further classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer is caused by smoking tobacco, or second ha......
  • Peripheral T-Cell Lymphomas (PTCL) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019
    Published: 15-Jan-2019        Price: US 2250 Onwards        Pages: 120
    Introduction DelveInsight's, "Peripheral T-Cell Lymphomas (PTCL) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Peripheral T-Cell Lymphomas (PTCL) . The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country. Global API Manufacturers of Marketed Products for......
  • Hematopoietic Stem Cell Transplantation - Market Insight, Epidemiology and Market Forecast - 2028
    Published: 15-Jan-2019        Price: US 6250 Onwards        Pages: 100
    DelveInsight's "Hematopoietic Stem Cell Transplantation - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Hematopoietic Stem Cell Transplantation epidemiology and market outlook for the 7MM. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 Hematopoietic Stem Cell Transplantation Understanding and Treatme......
  • Cervical Dysplasia - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 50
    "Cervical Dysplasia - Pipeline Insight, 2019" report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Cervical Dysplasia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Pr......
  • Soft Tissue Sarcoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019
    Published: 15-Jan-2019        Price: US 2000 Onwards        Pages: 60
    Introduction DelveInsight's, "Soft Tissue Sarcoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Soft Tissue Sarcoma . The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country. Global API Manufacturers of Marketed Products for Soft Tissue Sarcoma Co......
  • Small Cell Lung Cancer - Epidemiology Forecast to 2028
    Published: 15-Jan-2019        Price: US 3250 Onwards        Pages: 50
    DelveInsight's "Small Cell Lung Cancer - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Small Cell Lung Cancer epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 Small Cell Lung Cancer Epidemiology The epidem......
  • Soft Tissue Sarcoma - Epidemiology Forecast to 2028
    Published: 15-Jan-2019        Price: US 3250 Onwards        Pages: 50
    DelveInsight's "Soft Tissue Sarcoma - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Soft Tissue Sarcoma epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 Soft Tissue Sarcoma Epidemiology The epidemiology se......
  • Non-Small Cell Lung Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019
    Published: 15-Jan-2019        Price: US 2000 Onwards        Pages: 60
    Introduction DelveInsight's, "Non-Small Cell Lung Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Non-Small Cell Lung Cancer . The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country. Global API Manufacturers of Marketed Products for Non-Small Cell ......
  • Indolent Lymphoma - Market Insight, Epidemiology and Market Forecast - 2028
    Published: 15-Jan-2019        Price: US 6250 Onwards        Pages: 100
    DelveInsight's "Indolent Lymphoma - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Indolent Lymphoma epidemiology and market outlook for the 7MM. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 Indolent Lymphoma Understanding and Treatment Algorithm The market report provides the overview of the......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs